Side-by-side financials for AUTL and AMGN. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AUTL | AMGN |
|---|---|---|
| Market cap | - | $183.41 B |
| US-listed rank | - | #79 |
| Revenue (latest FY) | $75.39M | $36.75B |
| Net income (latest FY) | -$287.53M | $7.71B |
| Net margin | -381.4% | 21.0% |
| P/E (trailing FY) | - | 23.8 |
| SEC filings | 305 | 1,011 |
In their latest fiscal years, Autolus Therapeutics plc reported $75.39M in revenue while AMGEN INC reported $36.75B.
Full pages: Autolus Therapeutics plc and AMGEN INC, or browse the full rankings.